For research purposes only

Cat. No BA94673138

Availability - up to 10 mg in stock
- larger amount can be synthesized in 8 weeks

Description of biological activity

Multidrug resistance (MDR). The compound reverses multidrug resistance of tumor cells and exhibits good pharmaceutical properties. At low concentrations, the compound enhanced the accumulation of <[3H]>vincristine in K562/ADM cells and reversed tumor cell MDR; inhibited K562/adriamycin-resistant cell growth [WO2006/45541 A1, 2006]. The compound was shown to be capable of interacting with hydrogen bond donors of P-170 glycoprotein via π-hydrogen-π interactions. It was also found to reverse vicristine resistance in K562/ADM cells in vitro [J. Med. Chem. 1997, 40, 2047-2052].

Keywords: Anti-cancer

TECHNICAL INFORMATION

MS-209, 5-{3-[4-(2,2-diphenylacetyl)piperazin-1-yl]-2-hydroxypropoxy}quinoline multidrug resistance (MDR).

IUPAC Name: MS-209, 5-{3-[4-(2,2-diphenylacetyl)piperazin-1-yl]-2-hydroxypropoxy}quinoline

CAS Number: 12916-58-1

Purity: > 96% chemical purity (LCMS)

REFERENCES

1. Bioorg.Med.Chem.Lett. 1999, 9, 659-662

Latest added compounds

5-(4-Hydroxy-4-methyl-isoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-(3-methyl-5-trifluoromethyl-1H-pyrazol-4-ylmethyl)-1H-thieno[2,3-d]pyrimidine-2,4-dione

Selective inhibitor of MCT1 with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited.

Anti-cancer

Inhibitors

 
5-(4-chlorophenyl)-N-{[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl}pyridine-3-carboxamide

selective inhibitor of Nav1.8 sodium channel (IC50 = 3 nM); for TRPV1, P2X2/3, Cav2.2 calcium channels, KCNQ2/3 potassium channels IC50 >10 µM

Analgesic

Inhibitors

 
1-[4-chloro-3-(trifluoromethyl)benzenesulfonyl]-4-[4-(5-methyl-1H-pyrazol-1-yl)benzoyl]piperazine

inhibitor of ubiquitin ligase Smad ubiquitination regulatory factor-1 (Smuf1)

Bone disorders

Inhibitors